NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that NovaBay’s i-Lid™ Cleanser with Neutrox will be added to the Vision Source Independent Optometry Network.
Vision Source is the largest independent optometry network in the country, representing 2,800 independent optometrist offices, which is larger than Wal-Mart, the nation’s largest optometry chain. The network searches out innovative products that will improve care for the hundreds of thousands of patients seen by more than 3,400 optometrists and clinicians in Vision Source’s network.
“i-Lid Cleanser is clearly an innovative product and we are pleased to offer it through our network spanning the US,” said John McCall, Senior Vice President of Vendor Relations for Vision Source. “i-Lid Cleanser is a product that our constituent base of optometrists will find useful to add to their regimens to care for patients with dry eye and blepharitis,” McCall said.
For NovaBay, the addition of i-Lid Cleanser to the Vision Source network brings a major increase in the number of eye doctors having convenient access to the product and in the number of patients who will benefit. “This is a tremendous opportunity for i-Lid Cleanser,” said Glenn Moro, NovaBay’s Vice President for Sales and Marketing. “Vision Source optometrists represent the largest concentration of optometrists in the country. This means i-Lid Cleanser will get into the hands of doctors that treat thousands of patients suffering from dry eye often associated with blepharitis.”
“Once optometrists try i-Lid Cleanser and see the results, we believe they will quickly realize that it offers a marked improvement in the standard of care for patients with common conditions like dry eye syndrome associated with blepharitis and Meibomitis,” added Dr. Ron Najafi, Chairman and CEO of NovaBay.
i-Lid Cleanser is the only eye care product to contain Neutrox™ (NovaBay’s proprietary and pure hypochlorous acid (HOCl)). Neutrox-containing products have been cleared by the Food & Drug Administration to clean skin and wounds. Labs tests show that Neutrox, a naturally occurring substance released by white blood cells as a first defense against microbial invaders, has potent antimicrobial activity, yet is non-toxic to mammalian cells. Moreover, in laboratory testing Neutrox also neutralizes bacterial toxins and breaks up biofilms.
Those properties make i-Lid Cleanser ideal for the routine cleansing of skin of patients who have common eye conditions like blepharitis, where Staph bacteria grow on eyelids, causing swelling, redness, inflammation, irritation and a crusty build-up. The condition affects an estimated 23 million Americans. Patients who’ve had blepharitis for years—along with their doctors—report that i-Lid has finally brought relief from the often-painful and potentially sight threatening condition (click here to watch video).
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its Hypochlorous Solution Family of FDA cleared commercial stage products: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™ for the dermatology market.
This release contains forward-looking statements and opinions regarding the commercial potential of i-Lid Cleanser, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. The words “believe” and “will” are intended to identify the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser, and the risk that potential customers will not perceive the benefits of i-Lid Cleanser to be the same as NovaBay believes. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
NovaBay i-Lid Cleanser Contacts (samples requests)
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson